Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...

Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest ...

Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Akero Therapeutics reports positive mid-stage data for efruxifermin - its candidate treatment for cirrhosis. Akero stock rallied over 100%.

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...